Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.

Uraki R.; Ito M.; Kiso M.; Yamayoshi S.; Iwatsuki-Horimoto K.; Furusawa Y.; Sakai-Tagawa Y.; Imai M.; Koga M.; Yamamoto S.; Adachi E.; Saito M.; Tsutsumi T.; Otani A.; Kikuchi T.; Yotsuyanagi H.; Halfmann PJ.; Pekosz A.; Kawaoka Y.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.

Uraki R., Ito M., Kiso M., Yamayoshi S., Iwatsuki-Horimoto K., Furusawa Y., Sakai-Tagawa Y., Imai M., Koga M., Yamamoto S., Adachi E., Saito M., Tsutsumi T., Otani A., Kikuchi T., Yotsuyanagi H., Halfmann PJ., Pekosz A., Kawaoka Y.

Original publication

DOI

10.1016/s1473-3099(23)00070-1

Type

Journal

The Lancet. Infectious diseases

Publication Date

04/2023

Volume

23

Pages

402 - 403

Addresses

Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.

Keywords

Humans, Vaccines, Combined, Antiviral Agents, COVID-19, COVID-19 Vaccines